XML 49 R19.htm IDEA: XBRL DOCUMENT v3.22.4
Goodwill and Intangible Assets
 12 Months Ended
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets GOODWILL AND INTANGIBLE ASSETS
    
Changes in the carrying amount of goodwill, by reportable segment, were as follows (in millions):
CSCA(1)
CSCI(2)
Total
Balance at December 31, 2020$1,905.0 $1,190.7 $3,095.7 
Impairments(6.1)(10.0)(16.1)
Currency translation adjustments1.1 (81.3)(80.2)
Purchase accounting adjustments2.4 (2.4)— 
Balance at December 31, 20211,902.4 1,097.0 2,999.4 
Business acquisitions141.7 417.8 559.5 
Currency translation adjustments0.3 (68.8)(68.5)
Balance at December 31, 2022$2,044.4 $1,446.0 $3,490.4 

(1) We had accumulated goodwill impairments of $6.1 million as of December 31, 2022.
(2) We had accumulated goodwill impairments of $878.4 million as of December 31, 2022 and December 31, 2021.

As of December 31, 2022, we have three reporting units. Our CSCA operating segment is equivalent to our CSCA reporting unit. Our CSCI operating segment includes two reporting units, CSCI and Rare Diseases.
During the three months ended December 31, 2021, we reorganized the reporting structure within our CSCI segment following the integration of our reporting units into a new operating structure. The goodwill previously included in the Oral Care International, CSC UK and Australia, and BCS reporting units were combined into a then single CSCI reporting unit. Impairment tests were performed for the legacy reporting units prior to the reorganization and for the CSCI reporting unit immediately after the reorganization.

In conjunction with our 2021 annual impairment test, during the three months ended December 31, 2021, we recorded an impairment charge in our Oral Care International reporting unit within our CSCI segment of $10.0 million. The change in fair value from previous estimates was driven by reduced projections of future cash flows resulting from increased costs throughout the global supply chain (refer to Note 10).

Intangible Assets

Intangible assets and the related accumulated amortization consisted of the following (in millions):
Year Ended
 December 31, 2022December 31, 2021
 GrossAccumulated
Amortization		GrossAccumulated
Amortization
Indefinite-lived intangibles: (1)
Trademarks, trade names, and brands$3.2 $— $3.5 $— 
In-process research and development55.4 — 1.8 — 
Total indefinite-lived intangibles$58.6 $— $5.3 $— 
Definite-lived intangibles:
Distribution and license agreements and supply agreements$94.9 $58.1 $73.2 $56.9 
Developed product technology, formulations, and product rights484.8 211.8 300.2 191.4 
Customer relationships and distribution networks1,825.1 965.9 1,820.7 887.8 
Trademarks, trade names, and brands2,542.2 481.0 1,482.3 394.2 
Non-compete agreements2.0 2.0 2.1 2.1 
Total definite-lived intangibles$4,949.0 $1,718.8 $3,678.5 $1,532.4 
Total intangible assets$5,007.6 $1,718.8 $3,683.8 $1,532.4 
(1) Certain intangible assets are denominated in currencies other than U.S. dollar; therefore, their gross and net carrying values are subject to foreign currency movements.

On March 17, 2022, we announced that we received final approval from the U.S. Food and Drug Administration for the over-the-counter use of Nasonex®24HR Allergy (mometasone furoate monohydrate 50mcg). The approval triggered a $10.0 million milestone payment to the licensor, which was made in the second quarter of 2022 and capitalized as a definite-lived intangible asset.

We recorded an impairment charge of $0.9 million on certain IPR&D assets during the year ended December 31, 2021 due to changes in the projected development and regulatory timelines for various projects. We did not record any impairment charges in 2022 or 2020.

The remaining weighted-average useful life for our amortizable intangible assets by asset class at December 31, 2022 was as follows:
Amortizable Intangible Asset CategoryRemaining Weighted-Average Useful Life (Years)
Distribution and license agreements and supply agreements14
Developed product technology, formulations, and product rights14
Customer relationships and distribution networks14
Trademarks, trade names, and brands17

We recorded amortization expense of $252.4 million, $210.0 million, and $212.2 million during the years ended December 31, 2022, December 31, 2021, and December 31, 2020, respectively.
Our estimated future amortization expense is as follows (in millions):
YearAmount
2023$275.8 
2024238.0 
2025231.4 
2026223.8 
2027218.3 
Thereafter2,042.9